Nassif David W. 4
4 · Sio Gene Therapies Inc. · Filed Dec 9, 2021
Insider Transaction Report
Form 4
Nassif David W.
Principal Financial Officer
Transactions
- Tax Payment
Common Stock
2021-12-08$1.42/sh−6,294$8,937→ 45,244 total - Award
Common Stock
2021-12-08+17,534→ 51,538 total - Disposition to Issuer
Restricted Stock Units
2021-12-08−17,534→ 35,066 total→ Common Stock (17,534 underlying)
Footnotes (3)
- [F1]The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units.
- [F2]Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on April 15, 2021 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.
- [F3]50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.